{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:03:37Z","timestamp":1789815817309,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"DOI":"10.1007\/s40801-026-00583-5","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:05:19Z","timestamp":1789812319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and Treatment Patterns of Early Stage Melanoma: Results from a Multisite Chart Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-274X","authenticated-orcid":false,"given":"Collin M.","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-1921","authenticated-orcid":false,"given":"Maria L.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Gaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-2284","authenticated-orcid":false,"given":"Adina","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-1345","authenticated-orcid":false,"given":"Jara","family":"Majuelos-Melguizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Delibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-4970","authenticated-orcid":false,"given":"Rosemarie","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Fukunaga-Kalabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawab","family":"Qizilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-9830","authenticated-orcid":false,"given":"Irene M.","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-7961","authenticated-orcid":false,"given":"Xiang-Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"11","key":"583_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","volume":"159","author":"NM Helvind","year":"2023","unstructured":"Helvind NM, Brinch-M\u00f8ller Weitemeyer M, Chakera AH, Hendel HW, Elleb\u00e6k E, Svane IM, et al. Stage-specific risk of recurrence and death from melanoma in Denmark, 2008\u20132021: a national observational cohort study of 25,720 patients with stage IA to IV melanoma. JAMA Dermatol. 2023;159(11):1213\u201322.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"583_CR2","volume":"16","author":"OE Okobi","year":"2024","unstructured":"Okobi OE, Abreo E, Sams NP, Chukwuebuni OH, Tweneboa Amoako LA, Wiredu B, et al. Trends in melanoma incidence, prevalence, stage at diagnosis, and survival: an analysis of the United States Cancer Statistics (USCS) database. Cureus. 2024;16(10):e70697.","journal-title":"Cureus"},{"key":"583_CR3","unstructured":"B\u00f8nnelykke-Behrndtz ML, Steiniche T. Ulcerated melanoma: aspects and prognostic impact. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy, Brisbane. 2017."},{"issue":"2","key":"583_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/his.13060","volume":"70","author":"H Rashed","year":"2017","unstructured":"Rashed H, Flatman K, Bamford M, Teo KW, Saldanha G. Breslow density is a novel prognostic feature in cutaneous malignant melanoma. Histopathology. 2017;70(2):264\u201372.","journal-title":"Histopathology"},{"issue":"36","key":"583_CR5","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"7","key":"583_CR6","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","volume":"26","author":"DC Thomas","year":"2019","unstructured":"Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, et al. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival. Ann Surg Oncol. 2019;26(7):2254\u201362.","journal-title":"Ann Surg Oncol"},{"key":"583_CR7","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN guidelines: cutaneous melanoma. 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1492."},{"issue":"3","key":"583_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamafacial.2016.1846","volume":"19","author":"AJ Rosko","year":"2017","unstructured":"Rosko AJ, Vankoevering KK, McLean SA, Johnson TM, Moyer JS. Contemporary management of early-stage melanoma: a systematic review. JAMA Facial Plast Surg. 2017;19(3):232\u20138.","journal-title":"JAMA Facial Plast Surg."},{"issue":"15","key":"583_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152690","volume":"16","author":"GM Vargas","year":"2024","unstructured":"Vargas GM, Farooq MS, Karakousis GC. Adjuvant therapy for high-risk stage II melanoma: current paradigms in management and future directions. Cancers (Basel). 2024;16(15):2690.","journal-title":"Cancers (Basel)"},{"key":"583_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081894","author":"I Prka\u010din","year":"2025","unstructured":"Prka\u010din I, Brki\u0107 A, Pondeljak N, Mokos M, Ga\u0107ina K, \u0160itum M. Adjuvant immunotherapy in stage IIB\/IIC melanoma: current evidence and future directions. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13081894.","journal-title":"Biomedicines"},{"issue":"10336","key":"583_CR11","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329.","journal-title":"Lancet"},{"issue":"10","key":"583_CR12","first-page":"743","volume":"29","author":"A Mahadevan","year":"2015","unstructured":"Mahadevan A, Patel VL, Dagoglu N. Radiation therapy in the management of malignant melanoma. Oncology (Williston Park). 2015;29(10):743\u201351.","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"583_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/CMR.0b013e328357d796","volume":"22","author":"KD Cromwell","year":"2012","unstructured":"Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012;22(5):376\u201385.","journal-title":"Melanoma Res"},{"issue":"1","key":"583_CR14","doi-asserted-by":"publisher","first-page":"2424708","DOI":"10.1080\/20450885.2024.2424708","volume":"11","author":"DJ Savage","year":"2024","unstructured":"Savage DJ, Switzer B, Parikh R, Song JM, Stanek C, Arbesman J, et al. Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up. Melanoma Manag. 2024;11(1):2424708.","journal-title":"Melanoma Manag."},{"issue":"10","key":"583_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.","journal-title":"PLoS Med"},{"issue":"32","key":"583_CR16","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.22.00202","volume":"40","author":"C Garbe","year":"2022","unstructured":"Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;40(32):3741\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"583_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1245\/s10434-016-5642-0","volume":"24","author":"AY Lee","year":"2017","unstructured":"Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939\u201346.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"583_CR18","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/jso.26214","volume":"122","author":"J Bleicher","year":"2020","unstructured":"Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, et al. Recurrence patterns in patients with stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122(8):1770\u20137.","journal-title":"J Surg Oncol"},{"key":"583_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/cej.0000000000000970","author":"K Kostev","year":"2025","unstructured":"Kostev K, Rodemer I, Alymova S, Konrad M. Factors associated with the likelihood of being diagnosed with stage I melanoma in Germany: a multicenter study on 12 648 patients from the ADOReg skin cancer registry. Eur J Cancer Prev. 2025. https:\/\/doi.org\/10.1097\/cej.0000000000000970.","journal-title":"Eur J Cancer Prev"},{"issue":"11","key":"583_CR20","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1245\/s10434-021-09773-7","volume":"28","author":"CS Harrell Shreckengost","year":"2021","unstructured":"Harrell Shreckengost CS, Tariq M, Farley CR, Zhang C, Delman KA, Kudchadkar RR, et al. The impact of obesity on surgically treated locoregional melanoma. Ann Surg Oncol. 2021;28(11):6140\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"583_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775\u201384.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"583_CR22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamadermatol.2014.635","volume":"150","author":"S Shen","year":"2014","unstructured":"Shen S, Wolfe R, McLean CA, Haskett M, Kelly JW. Characteristics and associations of high-mitotic-rate melanoma. JAMA Dermatol. 2014;150(10):1048\u201355.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"583_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302309","volume":"19","author":"A Buja","year":"2024","unstructured":"Buja A, Rugge M, Cozzolino C, Dossi F, Zorzi M, Vecchiato A, et al. Could the mitotic count improve personalized prognosis in melanoma patients? PLoS ONE. 2024;19(4):e0302309.","journal-title":"PLoS ONE"},{"issue":"30","key":"583_CR24","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41(30):4794\u2013820.","journal-title":"J Clin Oncol"},{"issue":"33","key":"583_CR25","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947\u201370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"583_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jso.27534","volume":"129","author":"P Malekzadeh","year":"2024","unstructured":"Malekzadeh P, Brady MS. Adjuvant therapy for stage IIB\u2009+\u2009IIC melanoma. J Surg Oncol. 2024;129(1):91\u20136.","journal-title":"J Surg Oncol"},{"issue":"1","key":"583_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41698-022-00321-4","volume":"6","author":"G Wan","year":"2022","unstructured":"Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, et al. Prediction of early-stage melanoma recurrence using clinical and histopathologic features. NPJ Precis Oncol. 2022;6(1):79.","journal-title":"NPJ Precis Oncol."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00583-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:05:21Z","timestamp":1789812321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00583-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":27,"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00583-5","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"2 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: CMC has received grants or contracts from the Chen Institute, Dermatology Foundation, and DeepX Health C and support for attending meetings and\/or travel from Melanoma Research Alliance, American Academy of Dermatology, and Chen Institute. EMG has received grants or contracts from Regeneron Pharmaceuticals, Immunocore Holdings, Iovance Biotherapeutics, and Bristol Myers Squibb and support for attending meetings and\/or travel from Regeneron and Iovance Biotherapeutics. MLW has received grants or contracts from the Department of Defense and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Catamount Medical Education. AS declares a leadership role in the Society of Interventional Radiology Medical Student Committee (unpaid). AG, JI, and XZ declare no competing interests (other than funding provided to their institutions for completion of the study\u2014see Funding section above). JM, KG, CR, AD, RB, and NQ are employed by OXON Epidemiology. In addition, NQ declares stock or stock options in OXON Epidemiology and has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from OXON Epidemiology. MFK, IS, and XLT are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and declare stock or stock options in Merck & Co., Inc., Rahway, NJ, USA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data supporting the findings of this study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki. The Ethics Committees that reviewed this retrospective observational study and granted approval were University of Virginia Institutional Review Board for Health Sciences Research (no. 2483; approval granted on 13 November 2023), Human Research Protection Program UCSF (no. 386135; 10 September 2023), Mayo Clinic IRB (no. 23-006555; 03 October 2023), and Cleveland Clinic Institutional Review Board (IRB) (no. DATA3423; 2 January 2024).","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been granted a waiver for Health Insurance Portability and Accountability Act (HIPAA) authorization, in accordance with applicable HIPAA regulations.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: XLT, IS, and NQ; methodology: XLT, IS, MFK, and NQ; data collection: CMC, EMG, JI, MLW, AS, XZ, and AG; software, validation, and formal analysis: CR; writing\u2014original draft: JM, KG, RB, and XLT; writing\u2014review and editing: all authors; visualization: JM and KG; supervision: AD, JM, KG, and NQ; and project administration: AD. All authors have read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}